Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:26:35.725Z.
Consensus retrieved: 2026-10-06T11:00:41.098Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:26:35.725Z.
Quote observation: 2026-10-06T16:20:33.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dc415426faeea94243f90b621652fa7a0c821697a1c80d34302805649897f4cf
Forward PE Ratio (N/A) = Dated Quote Price ($0.45) / Consensus Forward EPS ($-0.14)
FORWARD PE RATIO
N/A
Dyadic International, Inc.
Market Cap
$16.48M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Dyadic International, Inc. (DYAI) | $16.48M | N/A |
| Bionano Genomics, Inc. (BNGO)vs › | $16.75M | N/A |
| Palatin Technologies, Inc. (PTN)vs › | $16.76M | N/A |
| BioCardia, Inc. (BCDA)vs › | $16.07M | N/A |
| PAVmed Inc. (PAVM)vs › | $16.98M | N/A |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.01M | N/A |
| Lipocine Inc. (LPCN)vs › | $17.15M | N/A |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.72M | N/A |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.43M | N/A |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.42M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $0.45, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.14 | $-0.19 – $-0.08 | 1 | n/m |
| 2027-12-31 | $0.03 | $0.02 – $0.04 | 2 | 15.1x |
| 2028-12-31 | $-0.01 | $-0.01 – $-0.01 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
